Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
BUSINESS
Sumitomo’s Group Sales Halve in Q1 as Latuda LOE in US Takes Toll
Sumitomo Pharma’s group sales in the first quarter of FY2023 tanked by over 50% year on year as the loss of exclusivity of its flagship antipsychotic agent Latuda (lurasidone) in the US wreaked havoc on its earnings. In April-June, the…
To read the full story
Related Article
- Sumitomo Eyes Return to Core Operating Profit in FY2024, Pruning Roivant Shares
November 1, 2023
- Sumitomo Incurs 77 Billion Yen Operating Loss in FY2022 on Kynmobi Impairment Charge
May 16, 2023
- Sumitomo Gears Up for Post-Latuda Growth, Sets 2027 Target Sales to 600 Billion Yen
May 8, 2023
- Sumitomo Sees Sales Force as Asset to Lure Collabs; Rep Cut Not in the Cards though Trulicity Deal Ended
February 9, 2023
- Sumitomo Suffers 18.5 Billion Yen Net Loss in April-December on Kynmobi Woes
February 1, 2023
- Sumitomo Braced for Red Ink to Continue in FY2023 on Latuda LOE
November 1, 2022
- Sumitomo Posts 7.3 Billion Yen Net Loss in H1 on Kynmobi Write-Down
November 1, 2022
- Sumitomo to Incur 54 Billion Yen in Impairment Loss on Kynmobi
October 7, 2022
- Sumitomo’s Q1 Sales Zoom 22% on FX, Cancer Drug License Fee
August 1, 2022
- Sumitomo Pharma Likely to Miss 5-Year Biz Targets as COVID Hobbles US Launches
May 16, 2022
- Sumitomo’s FY2021 Sales Up 8.5% on Otsuka Pact, North America/China Growth; Chairman Tada to Retire
May 16, 2022
- Sumitomo Dainippon’s 9-Month Profit Sinks 33.5% on US Promotions, Other Factors
February 1, 2022
- Otsuka Collaboration “More Positive” than Solo Even If Profits Shared: Sumitomo Dainippon Chief
October 28, 2021
- Sumitomo Dainippon’s H1 Sales Surge 12.3% on Otsuka Deal
October 28, 2021
- Sumitomo Dainippon’s Q1 Sales Skid 2.0% on Lower Latuda Revenue
July 30, 2021
- Sumitomo Dainippon Sees 6.9% Sales Growth on Latuda, Diabetes Med; Name Change Announced
May 13, 2021
- Sumitomo Dainippon Logs Double-Digit Growth on Diabetes Meds: April-December
January 29, 2021
- Sumitomo Dainippon’s Half-Year Sales Up 13.4% on Latuda Growth
October 29, 2020
- Sumitomo Dainippon’s Q1 Sales Up 13.9% on Equa/EquMet Contribution
August 3, 2020
BUSINESS
- Sawai, Towa See Double-Digit Growth in H1, but Stick to Full-Year Forecasts amid Uncertainties
November 29, 2023
- Meiji Set to Start Supplying COVID Jab in Japan Next Fall-Winter
November 29, 2023
- Debut of Japan-Made COVID-19 Jab Is Momentous: Daiichi Sankyo President
November 29, 2023
- Rystiggo Now Available for gMG Patients in Japan: UCB
November 29, 2023
- Amylyx Sets Up Japan Arm to Bring ALS Drug across Pacific
November 28, 2023
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…